Vaso (VASO) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 12, 2024
Document Information Line Items
Entity Registrant Name	VASO CORPORATION
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		175,380,963
Amendment Flag	false
Entity Central Index Key	0000839087
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	0-18105
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-2871434
Entity Address, Address Line One	137 Commercial St.
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Plainview
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11803
City Area Code	(516)
Local Phone Number	997-4600
Entity Interactive Data Current	Yes
Title of 12(b) Security	None
No Trading Symbol Flag	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 25,652	$ 11,342
Short-term investments		13,979
Accounts and other receivables, net of an allowance for credit losses and commission adjustments of $9,615 at June 30, 2024 and $9,708 at December 31, 2023	7,213	12,377
Inventories, net	1,218	1,470
Deferred commission expense	3,316	3,285
Prepaid expenses and other current assets	2,392	1,717
Total current assets	40,889	45,099
Property and equipment, net of accumulated depreciation of $10,579 at June 30, 2024 and $10,538 at December 31, 2023	1,423	1,174
Operating lease right of use assets	2,328	1,949
Goodwill	15,556	15,588
Intangibles, net	1,489	1,406
Other assets, net	4,826	4,902
Investment in EECP Global	596	683
Deferred tax assets, net	4,956	4,956
Total assets	72,063	75,757
CURRENT LIABILITIES
Accounts payable	2,953	2,670
Accrued commissions	937	2,411
Accrued expenses and other liabilities	5,080	7,335
Finance lease liabilities - current	62	72
Operating lease liabilities - current	1,074	928
Sales tax payable	704	699
Income taxes payable	90	30
Deferred revenue - current portion	15,924	15,883
Notes payable - current portion	9	9
Total current liabilities	26,836	30,040
LONG-TERM LIABILITIES
Notes payable, net of current portion	1	6
Finance lease liabilities, net of current portion		25
Operating lease liabilities, net of current portion	1,254	1,020
Deferred revenue, net of current portion	15,776	16,317
Other long-term liabilities	1,475	1,506
Total long-term liabilities	18,506	18,874
COMMITMENTS AND CONTINGENCIES (NOTE N)
STOCKHOLDERS’ EQUITY
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at June 30, 2024 and December 31, 2023
Common stock, $.001 par value; 250,000,000 shares authorized; 185,689,050 and 185,627,383 shares issued at June 30, 2024 and December 31, 2023, respectively; 175,380,963 and 175,319,296 shares outstanding at June 30, 2024 and December 31, 2023, respectively	186	186
Additional paid-in capital	64,011	63,993
Accumulated deficit	(35,050)	(35,032)
Accumulated other comprehensive loss	(426)	(304)
Treasury stock, at cost, 10,308,087 shares at June 30, 2024 and December 31, 2023	(2,000)	(2,000)
Total stockholders’ equity	26,721	26,843
Total liabilities and stockholders' equity	72,063	75,757
Related Party
CURRENT ASSETS
Receivables due from related parties	1,098	929
CURRENT LIABILITIES
Due to related party	$ 3	$ 3

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts and other receivables, net of an allowance for credit losses and commission adjustments (in Dollars)	$ 9,615	$ 9,708
Property and equipment, net of accumulated depreciation (in Dollars)	$ 10,579	$ 10,538
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common Stock, shares Issued	185,689,050	185,627,383
Common Stock, shares Outstanding	175,380,963	175,319,296
Treasury stock at cost	10,308,087	10,308,087

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Total revenues	$ 20,226	$ 20,323	$ 38,963	$ 39,359
Cost of revenues
Total cost of revenues	8,075	7,627	15,895	15,101
Gross profit	12,151	12,696	23,068	24,258
Operating expenses
Selling, general and administrative	10,841	10,662	22,907	21,804
Research and development	205	217	396	375
Business combination transaction costs	109		238
Total operating expenses	11,155	10,879	23,541	22,179
Operating income (loss)	996	1,817	(473)	2,079
Other (expense) income
Interest and financing costs	(1)	(5)	(4)	(33)
Interest and other income, net	273	179	585	262
Loss on disposal of fixed assets	(1)	(1)	(2)	(2)
Total other income, net	271	173	579	227
Income (loss) before income taxes	1,267	1,990	106	2,306
Income tax expense	(112)	(9)	(124)	(19)
Net income (loss)	1,155	1,981	(18)	2,287
Other comprehensive income
Foreign currency translation loss	(21)	(210)	(122)	(195)
Comprehensive income (loss)	$ 1,134	$ 1,771	$ (140)	$ 2,092
Income (loss) per common share
- basic (in Dollars per share)	$ 0.01	$ 0.01	$ 0	$ 0.01
Weighted average common shares outstanding
- basic (in Shares)	175,365	174,159	175,242	173,895
- diluted (in Shares)	175,984	175,120	175,242	175,162
Managed IT systems and services
Revenues
Total revenues	$ 10,591	$ 10,435	$ 20,743	$ 20,709
Professional sales services
Revenues
Total revenues	9,110	9,140	17,237	17,265
Equipment sales and services
Revenues
Total revenues	525	748	983	1,385
Cost of managed IT systems and services
Cost of revenues
Total cost of revenues	6,009	5,693	11,968	11,527
Cost of professional sales services
Cost of revenues
Total cost of revenues	1,937	1,743	3,685	3,225
Cost of equipment sales and services
Cost of revenues
Total cost of revenues	$ 129	$ 191	$ 242	$ 349

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
- diluted	$ 0	$ 0.01	$ 0	$ 0.01

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in- Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2022	$ 185	$ (2,000)	$ 63,952	$ (39,837)	$ (233)	$ 22,067
Balance (in Shares) at Dec. 31, 2022	185,436,000	(10,308,000)
Share-based compensation			13			13
Foreign currency translation gain (loss)					15	15
Net Income (loss)				306		306
Balance at Mar. 31, 2023	$ 185	$ (2,000)	63,965	(39,531)	(218)	22,401
Balance (in Shares) at Mar. 31, 2023	185,436,000	(10,308,000)
Balance at Dec. 31, 2022	$ 185	$ (2,000)	63,952	(39,837)	(233)	22,067
Balance (in Shares) at Dec. 31, 2022	185,436,000	(10,308,000)
Net Income (loss)						2,287
Balance at Jun. 30, 2023	$ 185	$ (2,000)	63,979	(37,550)	(428)	24,186
Balance (in Shares) at Jun. 30, 2023	185,449,000	(10,308,000)
Balance at Mar. 31, 2023	$ 185	$ (2,000)	63,965	(39,531)	(218)	22,401
Balance (in Shares) at Mar. 31, 2023	185,436,000	(10,308,000)
Share-based compensation			15			15
Share-based compensation (in Shares)	13,000
Shares withheld for employee tax liability			(1)			(1)
Foreign currency translation gain (loss)					(210)	(210)
Net Income (loss)				1,981		1,981
Balance at Jun. 30, 2023	$ 185	$ (2,000)	63,979	(37,550)	(428)	24,186
Balance (in Shares) at Jun. 30, 2023	185,449,000	(10,308,000)
Balance at Dec. 31, 2023	$ 186	$ (2,000)	63,993	(35,032)	(304)	26,843
Balance (in Shares) at Dec. 31, 2023	185,627,000	(10,308,000)
Share-based compensation			9			9
Foreign currency translation gain (loss)					(101)	(101)
Net Income (loss)				(1,173)		(1,173)
Balance at Mar. 31, 2024	$ 186	$ (2,000)	64,002	(36,205)	(405)	25,578
Balance (in Shares) at Mar. 31, 2024	185,627,000	(10,308,000)
Balance at Dec. 31, 2023	$ 186	$ (2,000)	63,993	(35,032)	(304)	26,843
Balance (in Shares) at Dec. 31, 2023	185,627,000	(10,308,000)
Net Income (loss)						(18)
Balance at Jun. 30, 2024	$ 186	$ (2,000)	64,011	(35,050)	(426)	26,721
Balance (in Shares) at Jun. 30, 2024	185,689,000	(10,308,000)
Balance at Mar. 31, 2024	$ 186	$ (2,000)	64,002	(36,205)	(405)	25,578
Balance (in Shares) at Mar. 31, 2024	185,627,000	(10,308,000)
Share-based compensation			9			9
Share-based compensation (in Shares)	62,000
Foreign currency translation gain (loss)					(21)	(21)
Net Income (loss)				1,155		1,155
Balance at Jun. 30, 2024	$ 186	$ (2,000)	$ 64,011	$ (35,050)	$ (426)	$ 26,721
Balance (in Shares) at Jun. 30, 2024	185,689,000	(10,308,000)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net (loss) income	$ (18)	$ 2,287
Adjustments to reconcile net (loss) income to net
Depreciation and amortization	411	537
Loss from investment in EECP Global	87	125
Provision for credit losses and commission adjustments	64	44
Share-based compensation	18	28
Changes in operating assets and liabilities:
Accounts and other receivables	5,086	6,271
Inventories	232	(129)
Deferred commission expense	(31)	(156)
Prepaid expenses and other current assets	(122)	(884)
Other assets, net	51	(291)
Accounts payable	285	268
Accrued commissions	(1,379)	(1,613)
Accrued expenses and other liabilities	(2,358)	(2,853)
Sales tax payable	7	(194)
Income taxes payable	85	(3)
Deferred revenue	(500)	2,783
Due to related party	(169)	(354)
Other long-term liabilities	(31)	153
Net cash provided by operating activities	1,718	6,019
Cash flows from investing activities
Purchases of equipment and software	(787)	(360)
Loan to Achari	(343)
Purchases of short-term investments		(11,134)
Redemption of short-term investments	13,756	8,134
Net cash provided by (used in) investing activities	12,626	(3,360)
Cash flows from financing activities
Payroll taxes paid by withholding shares		(1)
Repayment of notes payable and finance lease obligations	(39)	(99)
Net cash used in financing activities	(39)	(100)
Effect of exchange rate differences on cash and cash equivalents	5	19
NET INCREASE IN CASH AND CASH EQUIVALENTS	14,310	2,578
Cash and cash equivalents - beginning of period	11,342	11,821
Cash and cash equivalents - end of period	25,652	14,399
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
Interest paid	4	10
Income taxes paid	47	23
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Initial recognition of operating lease right of use asset and liability	$ 863	$ 474

Organization and Plan of Operat

Organization and Plan of Operations	6 Months Ended
	Jun. 30, 2024
Organization and Plan of Operations [Abstract]
ORGANIZATION AND PLAN OF OPERATIONS	NOTE A – ORGANIZATION AND PLAN OF OPERATIONS Vaso Corporation was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries. Overview Vaso Corporation principally operates in three distinct business segments in the healthcare and information technology (“IT”) industries. We manage and evaluate our operations, and report our financial results, through these three business segments. ● IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services; ● Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE Healthcare (“GEHC”) into the healthcare provider middle market; and ● Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively. VasoTechnology VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). It currently consists of a managed network and security service division and a healthcare IT application VAR (value added reseller) division, VasoHealthcare IT. Its current offerings include: ● Managed radiology and imaging applications (channel partner of select vendors of healthcare IT products). ● Managed network infrastructure (routers, switches and other core equipment). ● Managed network transport (FCC licensed carrier reselling over 175 facility partners). ● Managed security services. VasoTechnology uses a combination of proprietary technology, methodology and third-party applications to deliver its value proposition. VasoHealthcare VasoHealthcare commenced operations in 2010, in conjunction with the Company’s execution of its exclusive sales representation agreement (“GEHC Agreement”) with GEHC to further the sale of certain healthcare capital equipment in the healthcare provider middle market. Sales of GEHC equipment by the Company have grown significantly since then. VasoHealthcare’s current offerings consist of: ● GEHC diagnostic imaging capital equipment and ultrasound systems. ● GEHC service agreements for the above equipment. ● GEHC training services for use of the above equipment. ● GEHC and third-party financial services. VasoMedical VasoMedical is the Company’s business division for its proprietary medical device operations, including the design, development, manufacturing, sales and service of various medical devices in the domestic and international markets and includes the Vasomedical Global and Vasomedical Solutions business units. These devices are primarily for cardiovascular monitoring and diagnostic systems. Its current offerings consist of: ● Biox™ series Holter monitors and ambulatory blood pressure recorders. ● ARCS ® ● MobiCare ® ● EECP ® This segment uses its extensive cardiovascular device knowledge coupled with its significant engineering resources to cost-effectively create and market its proprietary technology. It works with a global distribution network of channel partners to sell its products. It also provides engineering and OEM services to other medical device companies. Achari Business Combination Agreement As previously announced, the Company entered into a business combination agreement (the “Business Combination Agreement”), dated as of December 6, 2023, with Achari Ventures Holdings Corp. I, a Delaware corporation (“Achari”) (NASDAQ: AVHI), and Achari Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Achari (“Merger Sub”). The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Achari. Upon the closing of the Business Combination Agreement (the “Closing”), we anticipate that Achari will change its name to “Vaso Holdings Corp.” or an alternative name chosen by the Company and reasonably acceptable to Achari (“New Vaso”). The Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to collectively as the “Business Combination”. Upon the Closing, New Vaso would have authorized shares of Class A common stock and Class B common stock. The Business Combination Agreement establishes a pro forma equity value of the Company at approximately $176 million, at $10.00 per share of Class A common stock. As such, we believe that the current Vaso stockholders would receive approximately 17.6 million shares of Class A common stock and the current Achari shareholders would maintain between 500 thousand and 750 thousand shares of Class A common stock depending on Achari’s unpaid expenses at the Closing and presuming the redemption of all outstanding public shares of Achari on or prior to the Closing. In addition, current Achari warrant holders would have outstanding warrants to purchase a minimum of 8.25 million shares of Class A common stock at an exercise price of $11.50 per share. No shares of Class B common stock are expected to be outstanding immediately after the Business Combination. The Boards of Directors of Vaso and Achari have each approved the Business Combination, the consummation of which is subject to various customary closing conditions, including the filing and effectiveness of a Registration Statement on Form S-4, as amended or supplemented, (the “Registration Statement”) by Achari with the United States Securities and Exchange Commission (“SEC”), the filing of a proxy statement by Vaso with the SEC and clearance by the SEC, and the approval of a majority of shareholders of both Achari and Vaso of the proposed Business Combination. At the time of this filing, Achari shareholders have approved the Business Combination at a virtual meeting, and Vaso has scheduled a special shareholders meeting for August 26, 2024 seeking their approval as well (Vaso shareholders representing approximately 44% of Vaso’s outstanding shares have entered into support agreements upon the signing of the Business Combination Agreement committing them to vote in favor of the Business Combination). The Business Combination is expected to close in the third quarter of 2024.

Interim Statement Presentation

Interim Statement Presentation	6 Months Ended
	Jun. 30, 2024
Interim Statement Presentation [Abstract]
INTERIM STATEMENT PRESENTATION	NOTE B – INTERIM STATEMENT PRESENTATION Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Certain information and disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on April 1, 2024. These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company’s management. The Company evaluates its estimates and assumptions on an ongoing basis. Correction of Prior Period Financial Statements We record commission revenue for certain products in our professional sales service segment based on GEHC’s reporting and payment of such commissions to us. In late August 2023, GEHC informed the Company that its calculations for such products were partially inaccurate and had remitted excess commissions. The Company has taken immediate steps to implement additional internal control procedures whereby GEHC will provide additional information sufficient to assess the accuracy of such commission payments going forward. We assessed the materiality of this misstatement on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality, codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, (“ASC 250”) and concluded that the misstatements were not material to the prior annual or interim periods. Accordingly, in accordance with ASC 250 (SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements), we have increased the accumulated deficit at January 1, 2023 by $808,000 to reflect $1,010,000 lower commission revenue and $202,000 lower commission expense, and corrected the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income, Cash Flows, and Changes in Stockholders’ Equity for the three and six months ended June 30, 2023, and the related notes to revise for those misstatements that impacted such periods. The following are selected line items from the Company’s Condensed Consolidated Financial Statements illustrating the effect of these corrections: Consolidated Statement of Operations and Comprehensive Income Three months ended June 30, 2023 Six months ended June 30, 2023 (in thousands, except per share data) As Reported Adjustment As Revised As Reported Adjustment As Revised Revenues Professional sales services $ 9,254 $ (114 ) $ 9,140 $ 17,564 $ (299 ) $ 17,265 Cost of revenues Cost of professional sales services $ 1,766 $ (23 ) $ 1,743 $ 3,285 $ (60 ) $ 3,225 Gross Profit - professional sales services segment $ 7,488 $ (91 ) $ 7,397 $ 14,279 $ (239 ) $ 14,040 Operating income $ 1,908 $ (91 ) $ 1,817 $ 2,318 $ (239 ) $ 2,079 Net income $ 2,072 $ (91 ) $ 1,981 $ 2,526 $ (239 ) $ 2,287 Comprehensive income $ 1,862 $ (91 ) $ 1,771 $ 2,331 $ (239 ) $ 2,092 Income per common share - basic and diluted $ 0.01 $ (0.00 ) $ 0.01 $ 0.01 $ (0.00 ) $ 0.01 Consolidated Statement of Changes in Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity (in thousands) As Reported Adjustment As Revised As Reported Adjustment As Revised Balance at January 1, 2023 $ (39,029 ) $ (808 ) $ (39,837 ) $ 22,875 $ (808 ) $ 22,067 Net income $ 454 $ (148 ) $ 306 $ 454 $ (148 ) $ 306 Balance at March 31, 2023 $ (38,575 ) $ (956 ) $ (39,531 ) $ 23,357 $ (956 ) $ 22,401 Net income $ 2,072 $ (91 ) $ 1,981 $ 2,072 $ (91 ) $ 1,981 Balance at June 30, 2023 $ (36,503 ) $ (1,047 ) $ (37,550 ) $ 25,233 $ (1,047 ) $ 24,186 Consolidated Statement of Cash Flows Six months ended June 30, 2023 (in thousands) As Reported Adjustment As Revised Net income $ 2,526 $ (239 ) $ 2,287 Accounts and other receivables $ 5,972 $ 299 $ 6,271 Accrued commissions $ (1,553 ) $ (60 ) $ (1,613 ) Recently Issued Accounting Standards To Be Adopted In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740), Improvement to Income Tax Disclosures, which requires enhanced income tax disclosures, including disaggregation of information in the rate reconciliation table and disaggregated information related to income taxes paid. The ASU is effective for annual reporting periods beginning with the year ending December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvement to Reportable Segment Disclosures. This ASU enhances disclosures required for reportable segments in both annual and interim consolidated financial statements. The ASU, which requires retrospective application, is effective for annual reporting periods beginning with the year ending December 31, 2024, and interim periods beginning with the three months ending March 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements. Reclassifications Certain reclassifications have been made to prior year amounts to conform with the current year presentation.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2024
Revenue Recognition [Abstract]
REVENUE RECOGNITION	NOTE C – REVENUE RECOGNITION Disaggregation of Revenue The following tables present revenues disaggregated by our business operations and timing of revenue recognition: (in thousands) Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 Professional sales Professional sales service Equipment service Equipment IT segment segment segment Total IT segment segment segment Total Network services $ 9,470 $ - $ - $ 9,470 $ 8,946 $ - $ - $ 8,946 Software sales and support 1,121 - - 1,121 1,489 - - 1,489 Commissions - 9,110 - 9,110 - 9,140 - 9,140 Medical equipment sales - - 494 494 - - 716 716 Medical equipment service - - 31 31 - - 32 32 $ 10,591 $ 9,110 $ 525 $ 20,226 $ 10,435 $ 9,140 $ 748 $ 20,323 Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 Professional sales Professional sales service Equipment service Equipment IT segment segment segment Total IT segment segment segment Total Network services $ 18,413 $ - $ - $ 18,413 $ 17,984 $ - $ - $ 17,984 Software sales and support 2,330 - - 2,330 2,725 - - 2,725 Commissions - 17,237 - 17,237 - 17,265 - 17,265 Medical equipment sales - - 921 921 - - 1,322 1,322 Medical equipment service - - 62 62 - - 63 63 $ 20,743 $ 17,237 $ 983 $ 38,963 $ 20,709 $ 17,265 $ 1,385 $ 39,359 Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 Professional sales Professional sales service Equipment service Equipment IT segment segment segment Total IT segment segment segment Total Revenue recognized over time $ 8,804 $ - $ 87 $ 8,891 $ 9,357 $ - $ 131 $ 9,488 Revenue recognized at a point in time 1,787 9,110 438 11,335 1,078 9,140 617 10,835 $ 10,591 $ 9,110 $ 525 $ 20,226 $ 10,435 $ 9,140 $ 748 $ 20,323 Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 Professional sales Professional sales service Equipment service Equipment IT segment segment segment Total IT segment segment segment Total Revenue recognized over time $ 18,105 $ - $ 168 $ 18,273 $ 18,878 $ - $ 241 $ 19,119 Revenue recognized at a point in time 2,638 17,237 815 20,690 1,831 17,265 1,144 20,240 $ 20,743 $ 17,237 $ 983 $ 38,963 $ 20,709 $ 17,265 $ 1,385 $ 39,359 Transaction Price Allocated to Remaining Performance Obligations As of June 30, 2024, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $96.9 million, of which we expect to recognize revenue as follows: (in thousands) Fiscal years of revenue recognition 2024 2025 2026 Thereafter Unfulfilled performance obligations $ 25,528 $ 32,939 $ 11,439 $ 26,963 Contract Balances Contract receivables include trade receivables, net and long-term receivables (recorded in Other assets in the condensed consolidated balance sheets). In our VasoHealthcare business, we bill amounts for certain milestones in advance of customer acceptance of the underlying equipment. Such amounts aggregated approximately $31,696,000 and $32,194,000 at June 30, 2024 and December 31, 2023, respectively, and are classified in our condensed consolidated balance sheets as either current or long-term deferred revenue. In addition, we record a contract liability for amounts expected to be repaid to GEHC due to customer order reductions. Such amounts aggregated approximately $1,278,000 and $971,000 at June 30, 2024 and December 31, 2023, respectively, and are included in accrued expenses and other liabilities in our condensed consolidated balance sheets. In our VasoMedical business, we bill amounts for post-delivery services and varying duration service contracts in advance of performance. Such amounts aggregated approximately $4,000 and $6,000 at June 30, 2024 and December 31, 2023, respectively, and are classified in our condensed consolidated balance sheets as either current or long-term deferred revenue. During the three and six months ended June 30, 2024, we recognized approximately $2.9 million and $5.2 million of revenues, respectively, that were included in our contract liability balance at April 1, 2024 and January 1, 2024, respectively. The following table summarizes the Company’s contract receivable and contract liability balances: 2024 2023 Contract receivables - January 1 13,398 15,306 Contract receivables - June 30 8,408 9,232 Increase (decrease) (4,990 ) (6,074 ) Contract liabilities - January 1 33,589 33,861 Contract liabilities - June 30 33,160 35,090 Increase (decrease) (429 ) 1,229 The decrease in contract receivables in the first halves of 2024 and 2023 was due primarily to collections exceeding billings. Costs to Obtain or Fulfill a Contract In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which requires that incremental costs of obtaining a contract are recognized as an asset and amortized to expense in a pattern that matches the timing of the revenue recognition of the related contract. We have determined the only significant incremental costs incurred to obtain contracts with customers within the scope of Topic 606 are certain sales commissions paid to associates. In addition, the Company elected the practical expedient to recognize the incremental costs of obtaining a contract when incurred for contracts where the amortization period for the asset the Company would otherwise have recognized is one year or less. Under Topic 606, sales commissions applicable to service contracts exceeding one year have been capitalized and amortized ratably over the term of the contract. In our VHC IT business, commissions allocable to multi-year subscription contracts or multi-year post-contract support performance obligations are amortized to expense ratably over the terms of the multi-year periods. VHC IT commissions allocable to other elements are charged to expense at go-live or customer acceptance. In our professional sales services segment, commissions paid to our sales force are deferred until the underlying equipment is accepted by the customer. We recognized approximately $724,000 and $619,000 in the three months ended June 30, 2024 and 2023, respectively, and approximately $1,303,000 and $1,230,000 in the six months ended June 30, 2024 and 2023, respectively, of amortization related to these sales commission assets in “Cost of professional sales services”, and approximately $7,000 and $22,000 in the three months ended June 30, 2024 and 2023, respectively, and approximately $28,000 and $48,000 in the six months ended June 30, 2024 and 2023, respectively, of amortization in “Selling, general and administrative” expense, in our condensed consolidated statements of operations and comprehensive income (loss). At June 30, 2024 and December 31, 2023, our consolidated balance sheets include approximately $6,889,000 and $7,106,000, respectively, in capitalized sales commissions - primarily in our professional sales services segment - to be expensed in future periods, of which $3,316,000 and $3,285,000, respectively, is recorded in deferred commission expense and $3,573,000 and $3,821,000, respectively, representing the long-term portion, is included in other assets. Significant Judgments when Applying Topic 606 Contract transaction price is allocated to performance obligations using estimated stand-alone selling price. Judgment is required in estimating stand-alone selling price for each distinct performance obligation. We determine stand-alone selling price maximizing observable inputs such as stand-alone sales when they exist or substantive renewal price charged to clients. In instances where stand-alone selling price is not observable, we utilize an estimate of stand-alone selling price based on historical pricing and industry practices. Certain revenue we record in our professional sales service segment contains an estimate for variable consideration. Due to the tiered structure of our commission rate, which increases as annual targets are achieved, under Topic 606 we record revenue and deferred revenue at the rate we expect to be achieved by year end. We base our estimate of variable consideration on historical results of previous years’ achievement under the GEHC agreement. Such estimate is reviewed each quarter and adjusted as necessary. In addition, the Company records commissions for arranging financing at an estimated rate which is subject to later revision based on certain factors. The Company also records commission adjustments to contract liabilities in its professional sales service segment based on estimates of future order cancellations.

Segment Reporting and Concentra

Segment Reporting and Concentrations	6 Months Ended
	Jun. 30, 2024
Segment Reporting and Concentrations [Abstract]
SEGMENT REPORTING AND CONCENTRATIONS	NOTE D – SEGMENT REPORTING AND CONCENTRATIONS Vaso Corporation principally operates in three distinct business segments in the healthcare and information technology industries. We manage and evaluate our operations, and report our financial results, through these three reportable segments. ● IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services; ● Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GEHC into the healthcare provider middle market; and ● Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., primarily focuses on the design, manufacture, sale and service of proprietary medical devices. The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income and adjusted EBITDA (net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash stock-based compensation). Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below: (in thousands) Three months ended Six months ended 2024 2023 2024 2023 Revenues from external customers IT $ 10,591 $ 10,435 $ 20,743 $ 20,709 Professional sales service 9,110 9,140 17,237 17,265 Equipment 525 748 983 1,385 Total revenues $ 20,226 $ 20,323 $ 38,963 $ 39,359 Gross Profit IT $ 4,582 $ 4,742 $ 8,775 $ 9,182 Professional sales service 7,173 7,397 13,552 14,040 Equipment 396 557 741 1,036 Total gross profit $ 12,151 $ 12,696 $ 23,068 $ 24,258 Operating income (loss) IT $ (173 ) $ 163 $ (593 ) $ 53 Professional sales service 1,658 2,058 1,651 2,897 Equipment (291 ) (106 ) (585 ) (131 ) Corporate (198 ) (298 ) (946 ) (740 ) Total operating income (loss) $ 996 $ 1,817 $ (473 ) $ 2,079 Depreciation and amortization IT $ 167 $ 236 $ 322 $ 482 Professional sales service 25 21 47 41 Equipment 34 7 42 14 Corporate - - - - Total depreciation and amortization $ 226 $ 264 $ 411 $ 537 Capital expenditures IT $ 203 $ 137 $ 450 $ 222 Professional sales service 108 2 110 52 Equipment 3 73 227 86 Corporate - - - - Total cash capital expenditures $ 314 $ 212 $ 787 $ 360 (in thousands) June 30, December 31, Identifiable Assets IT $ 22,902 $ 22,425 Professional sales service 13,127 18,955 Equipment 6,767 7,114 Corporate 29,267 27,263 Total assets $ 72,063 $ 75,757 GE Healthcare accounted for 45% of revenue for both of the three-month periods ended June 30, 2024 and 2023, and 44% of revenue for both of the six-month periods ended June 30, 2024 and 2023. GE Healthcare also accounted for $3.6 million or 50%, and $9.3 million or 75%, of accounts and other receivables at June 30, 2024 and December 31, 2023, respectively. No other customer accounted for 10% or more of revenue.

Net Income Per Common Share

Net Income Per Common Share	6 Months Ended
	Jun. 30, 2024
Net Income Per Common Share [Abstract]
NET INCOME PER COMMON SHARE	NOTE E – NET INCOME PER COMMON SHARE Basic earnings per common share is based on the weighted average number of common shares outstanding, including vested restricted shares, without consideration of potential common stock. Diluted earnings per common share is based on the weighted average number of common and potential dilutive common shares outstanding. Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows: (in thousands) Three months ended Six months ended 2024 2023 2024 2023 Basic weighted average shares outstanding 175,365 174,159 175,242 173,895 Dilutive effect of unvested restricted shares 619 961 - 1,267 Diluted weighted average shares outstanding 175,984 175,120 175,242 175,162 The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and six months ended June 30, 2024 and 2023, because the effect of their inclusion would be anti-dilutive. (in thousands) Three months ended Six months ended 2024 2023 2024 2023 Restricted common stock grants - - 756 -

Short-Term Investments and Fina

Short-Term Investments and Financial Instruments	6 Months Ended
	Jun. 30, 2024
Short-Term Investments and Financial Instruments [Abstract]
SHORT-TERM INVESTMENTS AND FINANCIAL INSTRUMENTS	NOTE F – SHORT-TERM INVESTMENTS AND FINANCIAL INSTRUMENTS The Company’s short-term investments consist of bank deposits with yields based on underlying debt and equity securities and six-month US Treasury bills. The bank deposits are carried at fair value of $0 and approximately $424,000 at June 30, 2024 and December 31, 2023, respectively, and are classified as available-for-sale. Realized gains or losses on the bank deposits are included in net income. The US Treasury bills are classified as held-to-maturity and are carried at amortized cost of $0 and approximately $13,555,000 at June 30, 2024 and December 31, 2023, respectively. Their fair value at June 30, 2024 and December 31, 2023 is $0 and approximately $13,559,000, respectively, and the unrecognized holding (loss) gain is $0 for both the three and six months ended June 30, 2024. Cash and cash equivalents represent cash and short-term, highly liquid investments either in certificates of deposit, treasury bills, money market funds, or investment grade commercial paper issued by major corporations and financial institutions that generally have maturities of three months or less from the date of acquisition. The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The carrying amount of assets and liabilities including cash and cash equivalents, short-term investments, accounts receivable, prepaids, accounts payable, accrued expenses and other current liabilities approximated their fair value as of June 30, 2024 and December 31, 2023, due to the relative short maturity of these instruments. Property and equipment, intangible assets, capital lease obligations, and goodwill are not required to be re-measured to fair value on a recurring basis. These assets are evaluated for impairment if certain triggering events occur. If such evaluation indicates that impairment exists, the respective asset is written down to its fair value. The following table presents information about the Company’s assets measured at fair value as of June 30, 2024 and December 31, 2023: (in thousands) Quoted Prices Significant in Active Other Significant Balance Markets for Observable Unobservable as of Identical Assets Inputs Inputs June 30, (Level 1) (Level 2) (Level 3) 2024 Assets Cash equivalents invested in money market funds and treasury bills $ 24,582 $ - $ - $ 24,582 Quoted Prices Significant in Active Other Significant Balance Markets for Observable Unobservable as of Identical Assets Inputs Inputs December 31, (Level 1) (Level 2) (Level 3) 2023 Assets Cash equivalents invested in money market funds and treasury bills $ 10,522 $ - $ - $ 10,522 Bank deposits (included in short term investments) 424 424 $ 10,946 $ - $ - $ 10,946

Accounts and Other Receivables,

Accounts and Other Receivables, Net	6 Months Ended
	Jun. 30, 2024
Accounts and Other Receivables, Net [Abstract]
ACCOUNTS AND OTHER RECEIVABLES, NET	NOTE G – ACCOUNTS AND OTHER RECEIVABLES, NET The following table presents information regarding the Company’s accounts and other receivables as of June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, Trade receivables $ 15,025 $ 22,085 Unbilled receivables 1,803 - Allowance for credit losses and commission adjustments (9,615 ) (9,708 ) Accounts and other receivables, net $ 7,213 $ 12,377 Contract receivables under Topic 606 consist of trade receivables and unbilled receivables. Trade receivables include amounts due for shipped products and services rendered. Unbilled receivables represent variable consideration recognized in accordance with Topic 606 but not yet billable. Amounts recorded – billed and unbilled - under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change. Allowance for credit losses and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.

Inventories, Net

Inventories, Net	6 Months Ended
	Jun. 30, 2024
Inventories, Net [Abstract]
INVENTORIES, NET	NOTE H – INVENTORIES, NET Inventories, net of reserves, consist of the following: (in thousands) June 30, December 31, Raw materials $ 695 $ 832 Work in process 100 11 Finished goods 423 627 $ 1,218 $ 1,470 The Company maintained reserves for slow moving inventories of $170,000 and $163,000 at June 30, 2024 and December 31, 2023, respectively.

Goodwill and Other Intangibles

Goodwill and Other Intangibles	6 Months Ended
	Jun. 30, 2024
Goodwill and Other Intangibles [Abstract]
GOODWILL AND OTHER INTANGIBLES	NOTE I – GOODWILL AND OTHER INTANGIBLES Goodwill of $14,375,000 is allocated to the IT segment. The remaining $1,181,000 of goodwill is attributable to the FGE reporting unit within the Equipment segment. The components of the change in goodwill are as follows: (in thousands) Six months Year ended June 30, December 31, Beginning of period $ 15,588 $ 15,614 Foreign currency translation adjustment (32 ) (26 ) End of period $ 15,556 $ 15,588 The Company’s other intangible assets consist of capitalized customer-related intangibles, patent and technology costs, and software costs, as set forth in the following: (in thousands) June 30, December 31, Customer-related Costs $ 5,831 $ 5,831 Accumulated amortization (4,888 ) (4,790 ) 943 1,041 Patents and Technology Costs 1,894 1,894 Accumulated amortization (1,894 ) (1,894 ) - - Software Costs 2,875 2,618 Accumulated amortization (2,329 ) (2,253 ) 546 365 $ 1,489 $ 1,406 Patents and technology are amortized on a straight-line basis over their estimated useful lives of ten and eight years, respectively. The cost of significant customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other customer-related intangible assets is amortized on a straight-line basis over the asset’s estimated economic life of seven years Amortization expense amounted to $101,000 and $90,000 for the three months ended June 30, 2024 and 2023, respectively, and $175,000 and $180,000 for the six months ended June 30, 2024 and 2023, respectively. Amortization of intangibles for the next five years is: (in thousands) Years ending December 31, Remainder of 2024 191 2025 286 2026 250 2027 221 2028 199 2029 47 $ 1,193

Other Assets, Net

Other Assets, Net	6 Months Ended
	Jun. 30, 2024
Other Assets, Net [Abstract]
OTHER ASSETS, NET	NOTE J – OTHER ASSETS, NET Other assets, net consist of the following at June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, Deferred commission expense - noncurrent $ 3,571 $ 3,821 Trade receivables - noncurrent 1,195 1,021 Other, net of allowance for loss on loan receivable of $412 at June 30, 2024 and December 31, 2023 60 60 $ 4,826 $ 4,902

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2024
Accrued Expenses and Other Liabilities [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE K – ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consist of the following at June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, Accrued compensation $ 977 $ 2,482 Accrued expenses - other 1,611 2,142 Order reduction liability 1,278 971 Other liabilities 1,214 1,740 $ 5,080 $ 7,335

Deferred Revenue

Deferred Revenue	6 Months Ended
	Jun. 30, 2024
Deferred Revenue [Abstract]
DEFERRED REVENUE	NOTE L – DEFERRED REVENUE The changes in the Company’s deferred revenues are as follows: (in thousands) Three months ended Six months ended 2024 2023 2024 2023 Deferred revenue at beginning of period $ 31,429 $ 31,553 $ 32,200 $ 30,803 Net additions: Deferred extended service contracts - - - 2 Deferred commission revenues 3,664 5,467 5,614 9,482 Recognized as revenue: Deferred extended service contracts (1 ) (1 ) (2 ) (2 ) Deferred commission revenues (3,393 ) (3,433 ) (6,112 ) (6,699 ) Deferred revenue at end of period 31,700 33,586 31,700 33,586 Less: current portion 15,924 16,859 15,924 16,859 Long-term deferred revenue at end of period $ 15,776 $ 16,727 $ 15,776 $ 16,727

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2024
Related-Party Transactions [Abstract]
RELATED-PARTY TRANSACTIONS	NOTE M – RELATED-PARTY TRANSACTIONS The Company uses the equity method to account for its interest in EECP Global as it has the ability to exercise significant influence over the entity and reports its share of EECP Global operations in Other Income (Expense) on its condensed consolidated statements of operations. For the three months ended June 30, 2024 and 2023, the Company’s share of EECP Global’s loss was approximately $56,000 and $47,000, respectively, and for the six months ended June 30, 2024 and 2023, the Company’s share of EECP Global’s loss was approximately $87,000 and $125,000, respectively, and included in Other (Expense) Income in its condensed consolidated statements of operations. At June 30, 2024 and December 31, 2023, the Company recorded a net receivable from related parties of approximately $1,072,000 and $901,000, respectively, on its condensed consolidated balance sheet for amounts due from EECP Global for fees and cost reimbursements net of amounts due to EECP Global for receivables collected on its behalf.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE N – COMMITMENTS AND CONTINGENCIES Litigation The Company is currently, and has been in the past, a party to various legal proceedings, primarily employee related matters, incident to its business. The Company believes that the outcome of all pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company. Sales Representation Agreement In October 2021, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010 and previously extended in 2012, 2015 and 2017. The amendment extended the term of the original agreement, which began on July 1, 2010, through December 31, 2026, subject to early termination by GEHC without cause with certain conditions. Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GEHC diagnostic imaging products to specific market accounts in the 48 contiguous states of the United States and the District of Columbia. The circumstances under which early termination of the agreement may occur with cause include: not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and not meeting various legal and GEHC policy requirements. Employment Agreements On May 10, 2019, the Company modified its Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, to provide for a five-year term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond May 31, 2026. The Employment Agreement provides for annual compensation of $500,000. Dr. Ma shall be eligible to receive a bonus for each fiscal year during the employment term. The amount and the occasion for payment of such bonus, if any, shall be at the discretion of the Board of Directors. Dr. Ma shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement. On December 31, 2022, the Company executed an Employment Agreement with the President of its VasoHealthcare subsidiary, Ms. Jane Moen, to provide for a twenty-seven month initial term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond December 31, 2026 or the earlier termination of the GEHC Agreement. The Employment Agreement provides for annual base compensation of $350,000. Ms. Moen shall be eligible to receive bonuses for each fiscal year during the employment term. The amount and the occasion for payment of such bonuses, if any, shall be based on employment status as well as achieving certain operating targets. Ms. Moen shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Interim Statement Presentation [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Certain information and disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on April 1, 2024. These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company’s management. The Company evaluates its estimates and assumptions on an ongoing basis.
Correction of Prior Period Financial Statements	Correction of Prior Period Financial Statements We record commission revenue for certain products in our professional sales service segment based on GEHC’s reporting and payment of such commissions to us. In late August 2023, GEHC informed the Company that its calculations for such products were partially inaccurate and had remitted excess commissions. The Company has taken immediate steps to implement additional internal control procedures whereby GEHC will provide additional information sufficient to assess the accuracy of such commission payments going forward. We assessed the materiality of this misstatement on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality, codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, (“ASC 250”) and concluded that the misstatements were not material to the prior annual or interim periods. Accordingly, in accordance with ASC 250 (SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements), we have increased the accumulated deficit at January 1, 2023 by $808,000 to reflect $1,010,000 lower commission revenue and $202,000 lower commission expense, and corrected the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income, Cash Flows, and Changes in Stockholders’ Equity for the three and six months ended June 30, 2023, and the related notes to revise for those misstatements that impacted such periods. The following are selected line items from the Company’s Condensed Consolidated Financial Statements illustrating the effect of these corrections: Consolidated Statement of Operations and Comprehensive Income Three months ended June 30, 2023 Six months ended June 30, 2023 (in thousands, except per share data) As Reported Adjustment As Revised As Reported Adjustment As Revised Revenues Professional sales services $ 9,254 $ (114 ) $ 9,140 $ 17,564 $ (299 ) $ 17,265 Cost of revenues Cost of professional sales services $ 1,766 $ (23 ) $ 1,743 $ 3,285 $ (60 ) $ 3,225 Gross Profit - professional sales services segment $ 7,488 $ (91 ) $ 7,397 $ 14,279 $ (239 ) $ 14,040 Operating income $ 1,908 $ (91 ) $ 1,817 $ 2,318 $ (239 ) $ 2,079 Net income $ 2,072 $ (91 ) $ 1,981 $ 2,526 $ (239 ) $ 2,287 Comprehensive income $ 1,862 $ (91 ) $ 1,771 $ 2,331 $ (239 ) $ 2,092 Income per common share - basic and diluted $ 0.01 $ (0.00 ) $ 0.01 $ 0.01 $ (0.00 ) $ 0.01 Consolidated Statement of Changes in Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity (in thousands) As Reported Adjustment As Revised As Reported Adjustment As Revised Balance at January 1, 2023 $ (39,029 ) $ (808 ) $ (39,837 ) $ 22,875 $ (808 ) $ 22,067 Net income $ 454 $ (148 ) $ 306 $ 454 $ (148 ) $ 306 Balance at March 31, 2023 $ (38,575 ) $ (956 ) $ (39,531 ) $ 23,357 $ (956 ) $ 22,401 Net income $ 2,072 $ (91 ) $ 1,981 $ 2,072 $ (91 ) $ 1,981 Balance at June 30, 2023 $ (36,503 ) $ (1,047 ) $ (37,550 ) $ 25,233 $ (1,047 ) $ 24,186 Consolidated Statement of Cash Flows Six months ended June 30, 2023 (in thousands) As Reported Adjustment As Revised Net income $ 2,526 $ (239 ) $ 2,287 Accounts and other receivables $ 5,972 $ 299 $ 6,271 Accrued commissions $ (1,553 ) $ (60 ) $ (1,613 )
Recently Issued Accounting Standards To Be Adopted	Recently Issued Accounting Standards To Be Adopted In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740), Improvement to Income Tax Disclosures, which requires enhanced income tax disclosures, including disaggregation of information in the rate reconciliation table and disaggregated information related to income taxes paid. The ASU is effective for annual reporting periods beginning with the year ending December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvement to Reportable Segment Disclosures. This ASU enhances disclosures required for reportable segments in both annual and interim consolidated financial statements. The ASU, which requires retrospective application, is effective for annual reporting periods beginning with the year ending December 31, 2024, and interim periods beginning with the three months ending March 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements.
Reclassifications	Reclassifications Certain reclassifications have been made to prior year amounts to conform with the current year presentation.

Interim Statement Presentation

Interim Statement Presentation (Tables)	6 Months Ended
	Jun. 30, 2024
Interim Statement Presentation [Abstract]
Schedule of Consolidated Statement of Operations and Comprehensive Income	The following are selected line items from the Company’s Condensed Consolidated Financial Statements illustrating the effect of these corrections: Consolidated Statement of Operations and Comprehensive Income Three months ended June 30, 2023 Six months ended June 30, 2023 (in thousands, except per share data) As Reported Adjustment As Revised As Reported Adjustment As Revised Revenues Professional sales services $ 9,254 $ (114 ) $ 9,140 $ 17,564 $ (299 ) $ 17,265 Cost of revenues Cost of professional sales services $ 1,766 $ (23 ) $ 1,743 $ 3,285 $ (60 ) $ 3,225 Gross Profit - professional sales services segment $ 7,488 $ (91 ) $ 7,397 $ 14,279 $ (239 ) $ 14,040 Operating income $ 1,908 $ (91 ) $ 1,817 $ 2,318 $ (239 ) $ 2,079 Net income $ 2,072 $ (91 ) $ 1,981 $ 2,526 $ (239 ) $ 2,287 Comprehensive income $ 1,862 $ (91 ) $ 1,771 $ 2,331 $ (239 ) $ 2,092 Income per common share - basic and diluted $ 0.01 $ (0.00 ) $ 0.01 $ 0.01 $ (0.00 ) $ 0.01
Schedule of Consolidated Statement of Changes in Stockholders’ Equity	Consolidated Statement of Changes in Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity (in thousands) As Reported Adjustment As Revised As Reported Adjustment As Revised Balance at January 1, 2023 $ (39,029 ) $ (808 ) $ (39,837 ) $ 22,875 $ (808 ) $ 22,067 Net income $ 454 $ (148 ) $ 306 $ 454 $ (148 ) $ 306 Balance at March 31, 2023 $ (38,575 ) $ (956 ) $ (39,531 ) $ 23,357 $ (956 ) $ 22,401 Net income $ 2,072 $ (91 ) $ 1,981 $ 2,072 $ (91 ) $ 1,981 Balance at June 30, 2023 $ (36,503 ) $ (1,047 ) $ (37,550 ) $ 25,233 $ (1,047 ) $ 24,186
Schedule of Consolidated Statement of Cash Flows	Consolidated Statement of Cash Flows Six months ended June 30, 2023 (in thousands) As Reported Adjustment As Revised Net income $ 2,526 $ (239 ) $ 2,287 Accounts and other receivables $ 5,972 $ 299 $ 6,271 Accrued commissions $ (1,553 ) $ (60 ) $ (1,613 )

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue Recognition [Abstract]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition	The following tables present revenues disaggregated by our business operations and timing of revenue recognition: (in thousands) Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 Professional sales Professional sales service Equipment service Equipment IT segment segment segment Total IT segment segment segment Total Network services $ 9,470 $ - $ - $ 9,470 $ 8,946 $ - $ - $ 8,946 Software sales and support 1,121 - - 1,121 1,489 - - 1,489 Commissions - 9,110 - 9,110 - 9,140 - 9,140 Medical equipment sales - - 494 494 - - 716 716 Medical equipment service - - 31 31 - - 32 32 $ 10,591 $ 9,110 $ 525 $ 20,226 $ 10,435 $ 9,140 $ 748 $ 20,323 Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 Professional sales Professional sales service Equipment service Equipment IT segment segment segment Total IT segment segment segment Total Network services $ 18,413 $ - $ - $ 18,413 $ 17,984 $ - $ - $ 17,984 Software sales and support 2,330 - - 2,330 2,725 - - 2,725 Commissions - 17,237 - 17,237 - 17,265 - 17,265 Medical equipment sales - - 921 921 - - 1,322 1,322 Medical equipment service - - 62 62 - - 63 63 $ 20,743 $ 17,237 $ 983 $ 38,963 $ 20,709 $ 17,265 $ 1,385 $ 39,359 Three Months Ended June 30, 2024 Three Months Ended June 30, 2023 Professional sales Professional sales service Equipment service Equipment IT segment segment segment Total IT segment segment segment Total Revenue recognized over time $ 8,804 $ - $ 87 $ 8,891 $ 9,357 $ - $ 131 $ 9,488 Revenue recognized at a point in time 1,787 9,110 438 11,335 1,078 9,140 617 10,835 $ 10,591 $ 9,110 $ 525 $ 20,226 $ 10,435 $ 9,140 $ 748 $ 20,323 Six Months Ended June 30, 2024 Six Months Ended June 30, 2023 Professional sales Professional sales service Equipment service Equipment IT segment segment segment Total IT segment segment segment Total Revenue recognized over time $ 18,105 $ - $ 168 $ 18,273 $ 18,878 $ - $ 241 $ 19,119 Revenue recognized at a point in time 2,638 17,237 815 20,690 1,831 17,265 1,144 20,240 $ 20,743 $ 17,237 $ 983 $ 38,963 $ 20,709 $ 17,265 $ 1,385 $ 39,359
Schedule of Transaction Price Allocated to Remaining Performance Obligations	As of June 30, 2024, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $96.9 million, of which we expect to recognize revenue as follows: (in thousands) Fiscal years of revenue recognition 2024 2025 2026 Thereafter Unfulfilled performance obligations $ 25,528 $ 32,939 $ 11,439 $ 26,963
Schedule of Contract Receivable and Contract Liability	The following table summarizes the Company’s contract receivable and contract liability balances: 2024 2023 Contract receivables - January 1 13,398 15,306 Contract receivables - June 30 8,408 9,232 Increase (decrease) (4,990 ) (6,074 ) Contract liabilities - January 1 33,589 33,861 Contract liabilities - June 30 33,160 35,090 Increase (decrease) (429 ) 1,229

Segment Reporting and Concent_2

Segment Reporting and Concentrations (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting and Concentrations [Abstract]
Schedule of Financial Information For Segments	Summary financial information for the segments is set forth below: (in thousands) Three months ended Six months ended 2024 2023 2024 2023 Revenues from external customers IT $ 10,591 $ 10,435 $ 20,743 $ 20,709 Professional sales service 9,110 9,140 17,237 17,265 Equipment 525 748 983 1,385 Total revenues $ 20,226 $ 20,323 $ 38,963 $ 39,359 Gross Profit IT $ 4,582 $ 4,742 $ 8,775 $ 9,182 Professional sales service 7,173 7,397 13,552 14,040 Equipment 396 557 741 1,036 Total gross profit $ 12,151 $ 12,696 $ 23,068 $ 24,258 Operating income (loss) IT $ (173 ) $ 163 $ (593 ) $ 53 Professional sales service 1,658 2,058 1,651 2,897 Equipment (291 ) (106 ) (585 ) (131 ) Corporate (198 ) (298 ) (946 ) (740 ) Total operating income (loss) $ 996 $ 1,817 $ (473 ) $ 2,079 Depreciation and amortization IT $ 167 $ 236 $ 322 $ 482 Professional sales service 25 21 47 41 Equipment 34 7 42 14 Corporate - - - - Total depreciation and amortization $ 226 $ 264 $ 411 $ 537 Capital expenditures IT $ 203 $ 137 $ 450 $ 222 Professional sales service 108 2 110 52 Equipment 3 73 227 86 Corporate - - - - Total cash capital expenditures $ 314 $ 212 $ 787 $ 360 (in thousands) June 30, December 31, Identifiable Assets IT $ 22,902 $ 22,425 Professional sales service 13,127 18,955 Equipment 6,767 7,114 Corporate 29,267 27,263 Total assets $ 72,063 $ 75,757

Net Income Per Common Share (Ta

Net Income Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2024
Net Income Per Common Share [Abstract]
Schedule of Reconciliation of Basic to Diluted Shares Used in the Earnings Per Share	A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows: (in thousands) Three months ended Six months ended 2024 2023 2024 2023 Basic weighted average shares outstanding 175,365 174,159 175,242 173,895 Dilutive effect of unvested restricted shares 619 961 - 1,267 Diluted weighted average shares outstanding 175,984 175,120 175,242 175,162
Schedule of Common Stock Equivalents that were Excluded from the Computation of Diluted Earnings Per Share	The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and six months ended June 30, 2024 and 2023, because the effect of their inclusion would be anti-dilutive. (in thousands) Three months ended Six months ended 2024 2023 2024 2023 Restricted common stock grants - - 756 -

Short-Term Investments and Fi_2

Short-Term Investments and Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2024
Short-Term Investments and Financial Instruments [Abstract]
Schedule of Assets Measured at Fair Value	The following table presents information about the Company’s assets measured at fair value as of June 30, 2024 and December 31, 2023: (in thousands) Quoted Prices Significant in Active Other Significant Balance Markets for Observable Unobservable as of Identical Assets Inputs Inputs June 30, (Level 1) (Level 2) (Level 3) 2024 Assets Cash equivalents invested in money market funds and treasury bills $ 24,582 $ - $ - $ 24,582 Quoted Prices Significant in Active Other Significant Balance Markets for Observable Unobservable as of Identical Assets Inputs Inputs December 31, (Level 1) (Level 2) (Level 3) 2023 Assets Cash equivalents invested in money market funds and treasury bills $ 10,522 $ - $ - $ 10,522 Bank deposits (included in short term investments) 424 424 $ 10,946 $ - $ - $ 10,946

Accounts and Other Receivable_2

Accounts and Other Receivables, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Accounts and Other Receivables, Net [Abstract]
Schedule of Accounts and Other Receivables	The following table presents information regarding the Company’s accounts and other receivables as of June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, Trade receivables $ 15,025 $ 22,085 Unbilled receivables 1,803 - Allowance for credit losses and commission adjustments (9,615 ) (9,708 ) Accounts and other receivables, net $ 7,213 $ 12,377

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Inventories, Net [Abstract]
Schedule of Inventories, Net	Inventories, net of reserves, consist of the following: (in thousands) June 30, December 31, Raw materials $ 695 $ 832 Work in process 100 11 Finished goods 423 627 $ 1,218 $ 1,470

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Other Intangibles [Abstract]
Schedule of Change in Goodwill	The components of the change in goodwill are as follows: (in thousands) Six months Year ended June 30, December 31, Beginning of period $ 15,588 $ 15,614 Foreign currency translation adjustment (32 ) (26 ) End of period $ 15,556 $ 15,588
Schedule of Other Intangible Assets	The Company’s other intangible assets consist of capitalized customer-related intangibles, patent and technology costs, and software costs, as set forth in the following: (in thousands) June 30, December 31, Customer-related Costs $ 5,831 $ 5,831 Accumulated amortization (4,888 ) (4,790 ) 943 1,041 Patents and Technology Costs 1,894 1,894 Accumulated amortization (1,894 ) (1,894 ) - - Software Costs 2,875 2,618 Accumulated amortization (2,329 ) (2,253 ) 546 365 $ 1,489 $ 1,406
Schedule of Amortization of Intangibles	Amortization of intangibles for the next five years is: (in thousands) Years ending December 31, Remainder of 2024 191 2025 286 2026 250 2027 221 2028 199 2029 47 $ 1,193

Other Assets, Net (Tables)

Other Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Other Assets, Net [Abstract]
Schedule of Other Assets, Net	Other assets, net consist of the following at June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, Deferred commission expense - noncurrent $ 3,571 $ 3,821 Trade receivables - noncurrent 1,195 1,021 Other, net of allowance for loss on loan receivable of $412 at June 30, 2024 and December 31, 2023 60 60 $ 4,826 $ 4,902

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Accrued Expenses and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consist of the following at June 30, 2024 and December 31, 2023: (in thousands) June 30, December 31, Accrued compensation $ 977 $ 2,482 Accrued expenses - other 1,611 2,142 Order reduction liability 1,278 971 Other liabilities 1,214 1,740 $ 5,080 $ 7,335

Deferred Revenue (Tables)

Deferred Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Deferred Revenue [Abstract]
Schedule of Deferred Revenues	The changes in the Company’s deferred revenues are as follows: (in thousands) Three months ended Six months ended 2024 2023 2024 2023 Deferred revenue at beginning of period $ 31,429 $ 31,553 $ 32,200 $ 30,803 Net additions: Deferred extended service contracts - - - 2 Deferred commission revenues 3,664 5,467 5,614 9,482 Recognized as revenue: Deferred extended service contracts (1 ) (1 ) (2 ) (2 ) Deferred commission revenues (3,393 ) (3,433 ) (6,112 ) (6,699 ) Deferred revenue at end of period 31,700 33,586 31,700 33,586 Less: current portion 15,924 16,859 15,924 16,859 Long-term deferred revenue at end of period $ 15,776 $ 16,727 $ 15,776 $ 16,727

Organization and Plan of Oper_2

Organization and Plan of Operations (Details) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Organization and Plan of Operations [Line items]
Pro forma equity value (in Dollars) | $	$ 176
Exercise price of per share (in Dollars per share) | $ / shares	$ 11.5
Vaso Stockholders [Member]
Organization and Plan of Operations [Line items]
Number of shares	17,600
Business Combination [Member]
Organization and Plan of Operations [Line items]
Business combination outstanding percentage	44%
Minimum [Member] | Achari Shareholders [Member]
Organization and Plan of Operations [Line items]
Number of shares	500
Maximum [Member] | Achari Shareholders [Member]
Organization and Plan of Operations [Line items]
Number of shares	750
Class A Common Stock [Member]
Organization and Plan of Operations [Line items]
Outstanding warrants to purchase shares	8,250
Class A Common Stock [Member] | Vaso Stockholders [Member]
Organization and Plan of Operations [Line items]
Pro forma equity value per share (in Dollars per share) | $ / shares	$ 10

Interim Statement Presentatio_2

Interim Statement Presentation (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jan. 01, 2023
Interim Statement Presentation [Line Items]
Lower commission revenue	$ 1,010,000
Lower commission expense	$ 202,000
Correction of Prior Period Financial Statements [Member]
Interim Statement Presentation [Line Items]
Accumulated deficit		$ 808,000

Interim Statement Presentatio_3

Interim Statement Presentation (Details) - Schedule of Consolidated Statement of Operations and Comprehensive Income - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024
As Reported [Member]
Revenues
Professional sales services	$ 9,254			$ 17,564
Cost of revenues
Cost of professional sales services	1,766			3,285
Gross Profit - professional sales services segment	7,488			14,279
Operating income	1,908			2,318
Net income	2,072	$ 2,072	$ 454	2,526
Comprehensive income	$ 1,862			$ 2,331
- Basic (in Dollars per share)	$ 0.01			$ 0.01
Adjustment [Member]
Revenues
Professional sales services	$ (114)			$ (299)
Cost of revenues
Cost of professional sales services	(23)			(60)
Gross Profit - professional sales services segment	(91)			(239)
Operating income	(91)			(239)
Net income	(91)	(91)	(148)	(239)
Comprehensive income	$ (91)			$ (239)
- Basic (in Dollars per share)	$ 0			$ 0
As Revised [Member]
Revenues
Professional sales services	$ 9,140			$ 17,265
Cost of revenues
Cost of professional sales services	1,743			3,225
Gross Profit - professional sales services segment	7,397			14,040
Operating income	1,817			2,079
Net income	1,981	$ 1,981	$ 306	2,287
Comprehensive income	$ 1,771			$ 2,092
- Basic (in Dollars per share)	$ 0.01			$ 0.01

Interim Statement Presentatio_4

Interim Statement Presentation (Details) - Schedule of Consolidated Statement of Operations and Comprehensive Income (Parentheticals) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
As Reported [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
- Diluted	$ 0.01	$ 0.01
Adjustment [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
- Diluted	0	0
As Revised [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
- Diluted	$ 0.01	$ 0.01

Interim Statement Presentatio_5

Interim Statement Presentation (Details) - Schedule of Consolidated Statement of Changes in Stockholders’ Equity - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
As Reported [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance		$ 23,357	$ 22,875		$ 22,875
Net income	$ 2,072	2,072	454	$ 2,526
Balance		25,233	23,357		25,233
Adjustment [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance		(956)	(808)		(808)
Net income	(91)	(91)	(148)	(239)
Balance		(1,047)	(956)		(1,047)
As Revised [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance		22,401	22,067		22,067
Net income	$ 1,981	1,981	306	$ 2,287
Balance		24,186	22,401		24,186
Accumulated Deficit [Member] | As Reported [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance		(38,575)	(39,029)		(39,029)
Net income		2,072	454
Balance		(36,503)	(38,575)		(36,503)
Accumulated Deficit [Member] | Adjustment [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance		(956)	(808)		(808)
Net income		(91)	(148)
Balance		(1,047)	(956)		(1,047)
Accumulated Deficit [Member] | As Revised [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance		(39,531)	(39,837)		(39,837)
Net income		1,981	306
Balance		$ (37,550)	$ (39,531)		$ (37,550)

Interim Statement Presentatio_6

Interim Statement Presentation (Details) - Schedule of Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024
As Reported [Member]
Schedule of Consolidated Statement of Cash Flows [Line Items]
Net income	$ 2,072	$ 2,072	$ 454	$ 2,526
Accounts and other receivables	5,972			5,972
Accrued commissions	(1,553)			(1,553)
Adjustment [Member]
Schedule of Consolidated Statement of Cash Flows [Line Items]
Net income	(91)	(91)	(148)	(239)
Accounts and other receivables	299			299
Accrued commissions	(60)			(60)
As Revised [Member]
Schedule of Consolidated Statement of Cash Flows [Line Items]
Net income	1,981	$ 1,981	$ 306	2,287
Accounts and other receivables	6,271			6,271
Accrued commissions	$ (1,613)			$ (1,613)

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Revenue Recognition [Line Items]
Aggregate amount of transaction price			$ 96,900,000
Deferred contract liabilities	$ 182,000		182,000		$ 419,000
Advance of customer acceptance of the underlying equipment	31,696,000		31,696,000		32,194,000
Contract liability expected to be repaid	1,278,000		1,278,000		971,000
Post-delivery services and varying duration service contracts	4,000		4,000		6,000
Revenues recognized	2,900,000		5,200,000
Amortization related to these sales commission assets	724,000	$ 619,000	1,303,000	$ 1,230,000
Amortization	7,000	$ 22,000	28,000	$ 48,000
Capitalized sales commissions			6,889,000		7,106,000
Deferred commission expense	3,316,000		3,316,000		3,285,000
Long-term portion of other assets	$ 3,573,000		$ 3,573,000		$ 3,821,000

Revenue Recognition (Details) -

Revenue Recognition (Details) - Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	$ 20,226	$ 20,323	$ 38,963	$ 39,359
Network Services [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	9,470	8,946	18,413	17,984
Software Sales and Support [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	1,121	1,489	2,330	2,725
Commissions [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	9,110	9,140	17,237	17,265
Medical Equipment Sales [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	494	716	921	1,322
Medical Equipment Service [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	31	32	62	63
IT Segment [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	10,591	10,435	20,743	20,709
IT Segment [Member] | Network Services [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	9,470	8,946	18,413	17,984
IT Segment [Member] | Software Sales and Support [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	1,121	1,489	2,330	2,725
IT Segment [Member] | Commissions [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
IT Segment [Member] | Medical Equipment Sales [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
IT Segment [Member] | Medical Equipment Service [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Professional Sales Service Segments [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	9,110	9,140	17,237	17,265
Professional Sales Service Segments [Member] | Network Services [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Professional Sales Service Segments [Member] | Software Sales and Support [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Professional Sales Service Segments [Member] | Commissions [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	9,110	9,140	17,237	17,265
Professional Sales Service Segments [Member] | Medical Equipment Sales [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Professional Sales Service Segments [Member] | Medical Equipment Service [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Equipment Segments [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	525	748	983	1,385
Equipment Segments [Member] | Network Services [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Equipment Segments [Member] | Software Sales and Support [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Equipment Segments [Member] | Commissions [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Equipment Segments [Member] | Medical Equipment Sales [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	494	716	921	1,322
Equipment Segments [Member] | Medical Equipment Service [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	31	32	62	63
Transferred over Time [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	8,891	9,488	18,273	19,119
Transferred over Time [Member] | IT Segment [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	8,804	9,357	18,105	18,878
Transferred over Time [Member] | Professional Sales Service Segments [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue
Transferred over Time [Member] | Equipment Segments [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	87	131	168	241
Transferred at Point in Time [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	11,335	10,835	20,690	20,240
Transferred at Point in Time [Member] | IT Segment [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	1,787	1,078	2,638	1,831
Transferred at Point in Time [Member] | Professional Sales Service Segments [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	9,110	9,140	17,237	17,265
Transferred at Point in Time [Member] | Equipment Segments [Member]
Schedule of Revenues Disaggregated By Our Business Operations and Timing of Revenue Recognition [Member]
Revenue	$ 438	$ 617	$ 815	$ 1,144

Revenue Recognition (Details)_2

Revenue Recognition (Details) - Schedule of Transaction Price Allocated to Remaining Performance Obligations $ in Thousands	Jun. 30, 2024 USD ($)
Revenue Recognition 2024 [Member]
Schedule of Transaction Price Allocated to Remaining Performance Obligations [Line Items]
Unfulfilled performance obligations	$ 25,528
Revenue Recognition 2025 [Member]
Schedule of Transaction Price Allocated to Remaining Performance Obligations [Line Items]
Unfulfilled performance obligations	32,939
Revenue Recognition 2026 [Member]
Schedule of Transaction Price Allocated to Remaining Performance Obligations [Line Items]
Unfulfilled performance obligations	11,439
Revenue Recognition Thereafter [Member]
Schedule of Transaction Price Allocated to Remaining Performance Obligations [Line Items]
Unfulfilled performance obligations	$ 26,963

Revenue Recognition (Details)_3

Revenue Recognition (Details) - Schedule of Contract Receivable and Contract Liability - Contracts [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenue Recognition (Details) - Schedule of Contract Receivable and Contract Liability [Line Items]
Contract receivables, beginning balance	$ 13,398	$ 15,306
Contract receivables, ending balance	8,408	9,232
Contract liabilities, beginning balance	33,589	33,861
Contract liabilities, ending balance	33,160	35,090
Increase (decrease) contract receivables	(4,990)	(6,074)
Increase (decrease) contract liabilities	$ (429)	$ 1,229

Segment Reporting and Concent_3

Segment Reporting and Concentrations (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023	Jun. 30, 2024 USD ($) segments	Jun. 30, 2023	Dec. 31, 2023 USD ($)
Segment Reporting and Concentrations [Line Items]
Number of reportable segments (in segments) | segments			3
Accounts and other receivables (in Dollars)	$ 7,213		$ 7,213		$ 12,377
GE Healthcare [Member] | Accounts and Other Receivables [Member]
Segment Reporting and Concentrations [Line Items]
Accounts and other receivables (in Dollars)	$ 3,600		$ 3,600		$ 9,300
Customer Concentration Risk [Member] | GE Healthcare [Member] | Revenue [Member]
Segment Reporting and Concentrations [Line Items]
Revenue percentage	45%	45%	44%	44%
Customer Concentration Risk [Member] | GE Healthcare [Member] | Accounts and Other Receivables [Member]
Segment Reporting and Concentrations [Line Items]
Revenue percentage			50%		75%

Segment Reporting and Concent_4

Segment Reporting and Concentrations (Details) - Schedule of Financial Information For Segments - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Revenues from external customers
Total revenues	$ 20,226	$ 20,323	$ 38,963	$ 39,359
Gross Profit
Total gross profit	12,151	12,696	23,068	24,258
Operating income (loss)
Total operating income	996	1,817	(473)	2,079
Depreciation and amortization
Total depreciation and amortization	226	264	411	537
Capital expenditures
Total cash capital expenditures	314	212	787	360
Identifiable Assets
Total assets	72,063		72,063		$ 75,757
Equipment [Member]
Revenues from external customers
Total revenues	525	748	983	1,385
Gross Profit
Total gross profit	396	557	741	1,036
Operating income (loss)
Total operating income	(291)	(106)	(585)	(131)
Depreciation and amortization
Total depreciation and amortization	34	7	42	14
Capital expenditures
Total cash capital expenditures	3	73	227	86
Identifiable Assets
Total assets	6,767		6,767		7,114
IT [Member]
Revenues from external customers
Total revenues	10,591	10,435	20,743	20,709
Gross Profit
Total gross profit	4,582	4,742	8,775	9,182
Operating income (loss)
Total operating income	(173)	163	(593)	53
Depreciation and amortization
Total depreciation and amortization	167	236	322	482
Capital expenditures
Total cash capital expenditures	203	137	450	222
Identifiable Assets
Total assets	22,902		22,902		22,425
Professional sales service [Member]
Revenues from external customers
Total revenues	9,110	9,140	17,237	17,265
Gross Profit
Total gross profit	7,173	7,397	13,552	14,040
Operating income (loss)
Total operating income	1,658	2,058	1,651	2,897
Depreciation and amortization
Total depreciation and amortization	25	21	47	41
Capital expenditures
Total cash capital expenditures	108	2	110	52
Identifiable Assets
Total assets	13,127		13,127		18,955
Corporate [Member]
Operating income (loss)
Total operating income	(198)	(298)	(946)	(740)
Depreciation and amortization
Total depreciation and amortization
Capital expenditures
Total cash capital expenditures
Identifiable Assets
Total assets	$ 29,267		$ 29,267		$ 27,263

Net Income Per Common Share (De

Net Income Per Common Share (Details) - Schedule of Reconciliation of Basic to Diluted Shares Used in the Earnings Per Share - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Reconciliation of Basic to Diluted Shares Used in the Earnings Per Share [Abstract]
Basic weighted average shares outstanding	175,365	174,159	175,242	173,895
Dilutive effect of unvested restricted shares	619	961		1,267
Diluted weighted average shares outstanding	175,984	175,120	175,242	175,162

Net Income Per Common Share (_2

Net Income Per Common Share (Details) - Schedule of Common Stock Equivalents that were Excluded from the Computation of Diluted Earnings Per Share - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restricted common stock grants [Member]
Schedule of Common Stock Equivalents that were Excluded from the Computation of Diluted Earnings Per Share [Line Items]
Restricted common stock grants			756

Short-Term Investments and Fi_3

Short-Term Investments and Financial Instruments (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
Short-Term Investments and Financial Instruments [Line Items]
Available-for-sale	$ 0	$ 0	$ 424,000
Held-to-maturity carried at amortized cost	0	0	13,555,000
Fair value of short term investment	0	0	$ 13,559,000
Unrecognized holding (loss) gain	$ 0	$ 0

Short-Term Investments and Fi_4

Short-Term Investments and Financial Instruments (Details) - Schedule of Assets Measured at Fair Value - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Assets
Assets		$ 10,946
Cash equivalents invested in money market funds and treasury bills [Member]
Assets
Assets	$ 24,582	10,522
Bank deposits (included in short term investments) [Member]
Assets
Assets		424
Fair Value, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets
Assets		10,946
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets
Assets
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets
Assets
Fair Value, Recurring [Member] | Cash equivalents invested in money market funds and treasury bills [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets
Assets	24,582	10,522
Fair Value, Recurring [Member] | Cash equivalents invested in money market funds and treasury bills [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets
Assets
Fair Value, Recurring [Member] | Cash equivalents invested in money market funds and treasury bills [Member] | Significant Unobservable Inputs (Level 3) [Member]
Assets
Assets
Fair Value, Recurring [Member] | Bank deposits (included in short term investments) [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets
Assets		$ 424

Accounts and Other Receivable_3

Accounts and Other Receivables, Net (Details) - Schedule of Accounts and Other Receivables - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Accounts and Other Receivables [Abstract]
Trade receivables	$ 15,025	$ 22,085
Unbilled receivables	1,803
Allowance for credit losses and commission adjustments	(9,615)	(9,708)
Accounts and other receivables, net	$ 7,213	$ 12,377

Inventories, Net (Details)

Inventories, Net (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Inventories, Net [Abstract]
Reserve for slow moving inventories	$ 170,000	$ 163,000

Inventories, Net (Details) - Sc

Inventories, Net (Details) - Schedule of Inventories, Net - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Inventories, Net [Abstract]
Raw materials	$ 695	$ 832
Work in process	100	11
Finished goods	423	627
Inventories, net, Total	$ 1,218	$ 1,470

Goodwill and Other Intangible_2

Goodwill and Other Intangibles (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Other Intangibles [Line Items]
Goodwill	$ 15,556,000		$ 15,556,000		$ 15,588,000	$ 15,614,000
Amortization Expense	$ 101,000	$ 90,000	$ 175,000	$ 180,000
Maximum [Member]
Goodwill and Other Intangibles [Line Items]
Estimated useful lives	10 years		10 years
Minimum [Member]
Goodwill and Other Intangibles [Line Items]
Estimated useful lives	8 years		8 years
FGE Reporting Unit [Member]
Goodwill and Other Intangibles [Line Items]
Goodwill	$ 1,181,000		$ 1,181,000
IT Segment [Member]
Goodwill and Other Intangibles [Line Items]
Goodwill	$ 14,375,000		$ 14,375,000

Goodwill and Other Intangible_3

Goodwill and Other Intangibles (Details) - Schedule of Change in Goodwill - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Schedule of Change in Goodwill [Abstract]
Beginning of period	$ 15,588	$ 15,614
Foreign currency translation adjustment	(32)	(26)
End of period	$ 15,556	$ 15,588

Goodwill and Other Intangible_4

Goodwill and Other Intangibles (Details) - Schedule of Other Intangible Assets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Other Intangible Assets [Line Items]
Intangible assets, net	$ 1,489	$ 1,406
Customer-related [Member]
Schedule of Other Intangible Assets [Line Items]
Costs	5,831	5,831
Accumulated amortization	(4,888)	(4,790)
Intangible assets, net	943	1,041
Patents and Technology [Member]
Schedule of Other Intangible Assets [Line Items]
Costs	1,894	1,894
Accumulated amortization	(1,894)	(1,894)
Intangible assets, net
Software [Member]
Schedule of Other Intangible Assets [Line Items]
Costs	2,875	2,618
Accumulated amortization	(2,329)	(2,253)
Intangible assets, net	$ 546	$ 365

Goodwill and Other Intangible_5

Goodwill and Other Intangibles (Details) - Schedule of Amortization of Intangibles $ in Thousands	Jun. 30, 2024 USD ($)
Schedule of Amortization of Intangibles [Abstract]
Remainder of 2024	$ 191
2025	286
2026	250
2027	221
2028	199
2029	47
Intangible assets, net	$ 1,193

Other Assets, Net (Details) - S

Other Assets, Net (Details) - Schedule of Other Assets, Net - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Other Assets, Net [Abstract]
Deferred commission expense - noncurrent	$ 3,571	$ 3,821
Trade receivables - noncurrent	1,195	1,021
Other, net of allowance for loss on loan receivable of $412 at June 30, 2024 and December 31, 2023	60	60
Total other assets net	$ 4,826	$ 4,902

Other Assets, Net (Details) -_2

Other Assets, Net (Details) - Schedule of Other Assets, Net (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Other Assets, Net [Abstract]
Other, net of allowance for loss on loan receivable	$ 412	$ 412

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of Accrued Expenses and Other Liabilities - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Accrued Expenses and Other Liabilities [Abstract]
Accrued compensation	$ 977	$ 2,482
Accrued expenses - other	1,611	2,142
Order reduction liability	1,278	971
Other liabilities	1,214	1,740
Accrued expenses and other liabilities	$ 5,080	$ 7,335

Deferred Revenue (Details) - Sc

Deferred Revenue (Details) - Schedule of Deferred Revenues - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Schedule of Deferred Revenues [Line Items]
Contract liabilities, beginning balance	$ 31,429	$ 31,553	$ 32,200	$ 30,803
Net additions:
Net additions			(500)	2,783
Recognized as revenue:
Recognized as revenue	(2,900)		(5,200)
Contract liabilities, ending balance	31,700	33,586	31,700	33,586
Less: current portion	15,924	16,859	15,924	16,859	$ 15,883
Long-term deferred revenue at end of period	15,776	16,727	15,776	16,727	$ 16,317
Deferred extended service contracts [Member]
Net additions:
Net additions				2
Recognized as revenue:
Recognized as revenue	(1)	(1)	(2)	(2)
Deferred commission revenues [Member]
Net additions:
Net additions	3,664	5,467	5,614	9,482
Recognized as revenue:
Recognized as revenue	$ (3,393)	$ (3,433)	$ (6,112)	$ (6,699)

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Related-Party Transactions [Line Items]
EECP global’s loss		$ 47,000	$ 87,000	$ 125,000
Related Party [Member]
Related-Party Transactions [Line Items]
Net receivable from related parties	$ 1,072,000		$ 1,072,000		$ 901,000
EECP [Member]
Related-Party Transactions [Line Items]
EECP global’s loss	$ 56,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Dec. 31, 2022	May 10, 2019
Commitments and Contingencies [Abstract]
Employment agreement for annual compensation	$ 350,000	$ 500,000